LSM1: A Potential Cancer Drug Target Or Biomarker (G27257)

Target Name: LSM1

NCBI ID: G27257

LSM1

LSM1: A Potential Cancer Drug Target Or Biomarker

Cancer-associated Sm-like (LSM1) is a protein that has been identified as a potential drug target or biomarker in the field of cancer. LSM1 is a member of the Sm-like protein family, which includes several other proteins that have been implicated in cancer development and progression.

The Sm-like protein family plays a crucial role in cell signaling, particularly in the regulation of cell division and apoptosis (programmed cell death). LSM1 is known to be involved in several cellular processes, including cell signaling, cell adhesion, and cell survival.

One of the key functions of LSM1 is its role in the regulation of cell division. LSM1 has been shown to play a role in the regulation of mitosis, a critical process in cell division that is essential for the development and progression of cancer.

In addition to its role in cell division, LSM1 is also involved in the regulation of cell adhesion. Adhesion is the process by which cells stick together and form tissues. LSM1 has been shown to be involved in the regulation of cell adhesion, which is a critical process for the development and maintenance of tissues and organs.

Another function of LSM1 is its role in cell survival. LSM1 has been shown to play a role in the regulation of apoptosis, which is the process by which cells die and are removed from the body. This is important for maintaining tissue homeostasis and for the regulation of immune responses.

The potential drug target or biomarker properties of LSM1 are derived from its involvement in cell signaling and cell division. LSM1 has been shown to be a potential drug target by its ability to interact with and inhibit the activity of several tyrosine kinases, which are involved in cell signaling. In addition, LSM1 has been shown to be involved in the regulation of cell adhesion, which is an attractive target for biomarkers that can be used to monitor the progression of cancer.

In conclusion, LSM1 is a protein that has been identified as a potential drug target or biomarker in the field of cancer. Its involvement in cell signaling and cell division, as well as its role in cell adhesion and apoptosis, make it an attractive target for the development of new treatments for cancer. Further research is needed to fully understand the biology of LSM1 and its potential as a drug target or biomarker.

Protein Name: LSM1 Homolog, MRNA Degradation Associated

Functions: Plays a role in the degradation of histone mRNAs, the only eukaryotic mRNAs that are not polyadenylated (PubMed:18172165). Probably also part of an LSm subunits-containing complex involved in the general process of mRNA degradation (By similarity)

The "LSM1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LSM1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets